Assessment Pembrolizumab (Keytruda): CADTH Reimbursement Suggestion: Indication: In combination with chemotherapy, to the treatment of adult clients with domestically recurrent unresectable or metastatic triple-negative breast cancer that have not received prior chemotherapy for metastatic condition